Catalyst
Slingshot members are tracking this event:
Neurocrine Announces INGREZZA (valbenazine) New Drug Application for the Treatment of Tardive Dyskinesia has been Accepted for Priority Review by U.S. FDA
Do you think this event is important to the companies below? How will it affect their stock price?
| Related Companies | Importance
|
Impact on Stocks
|
||||
|---|---|---|---|---|---|---|
| NBIX | Community voting in process | |||||
Slingshot Insights Explained
Catalyst Date
Occurred on:
Oct 11, 2016
Related Projects
-
Don’t see a project related to the catalyst you care about?
Related Keywords
Valbenazine, Ingrezza, Tardive Dyskinesia
